Oxygenta Pharmaceutical Share Price
47.05+0.00 (+0.00%)
-27.47% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
Share Price Live Stats
No results found
Share Market Cap & Key Ratios Overview
No results found
About
No results found
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
No results found
Oxygenta Pharmaceutical Share Price
47.05+0.00 (+0.00%)
-27.47% past 1 Year
Financial overview
Peer Comparison
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Balance Sheet
Consolidated
Standalone
₹
%
Cash Flow
Consolidated
Standalone
₹
%
Fundamental Ratios
Consolidated
Standalone
Oxygenta Pharmaceutical Share Price
47.05+0.00 (+0.00%)
-27.47% past 1 Year
Technical meters
No results found
Pivot
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Oxygenta Pharmaceutical Share Price
47.05+0.00 (+0.00%)
-27.47% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
No results found
Bulk & block deals
No results found
Insider trading & SAST
No results found
Oxygenta Pharmaceutical Share Price
47.05+0.00 (+0.00%)
-27.47% past 1 Year
Corporate Actions
Date
Type
Details
Company details
Oxygenta Pharmaceutical Share Price
47.05+0.00 (+0.00%)
-27.47% past 1 Year
Corporate filings & documents
No corporate filings & documents found
Oxygenta Pharmaceutical Share Price
47.05+0.00 (+0.00%)
-27.47% past 1 Year
News
Kotak Maintains Buy On SBI With Rs 1250 Target After Strong Q2 Earnings
Equity
SBIN
Nomura Maintains Neutral Rating On SBI With Rs 1100 Target Price
Equity
SBIN
Citi Maintains Buy Rating On SBI With Rs 1300 Target Price
Equity
SBIN
HSBC Maintains Buy Rating On SBI With Rs 1220 Target Price
Equity
SBIN
Bernstein Maintains Market Perform On SBI Amid Softer Underlying Earnings Performance
Equity
SBIN
CLSA Maintains Outperform Rating On SBI After Strong Q2 Operating Performance
Equity
SBIN
Macquarie Maintains Outperform Rating On SBI With Rs 1220 Target
Equity
SBIN
UBS Maintains Neutral View On SBI After Mixed Q2 Operating Performance
Equity
SBIN
Neuland Laboratories Reports Weak Q2 Amid Commercial CMS Order Volatility
Equity
NEULANDLAB
Solar Industries Q2 Growth Beats Estimates, Goldman Sachs Retains Buy Rating
Equity
SOLARINDS
Angel One October funding book and client base show strong year on year growth
Equity
ANGELONE
Citi Retains Sell Rating, Cuts Bata India Target Price To Rs 550
Equity
BATAINDIA
CLSA Maintains Outperform Rating On Max Healthcare With Rs 1160 Target
Equity
MAXHEALTH
Lupin Reports Lower Q2 EBITDA and Margin Despite Stronger Sales Growth
Equity
LUPIN
MGL Q2 FY27 Earnings Miss Estimates Amid Higher Gas Costs
Equity
MGL
Lupin Q2 Profit Declines Despite Revenue Growth Amid Margin Pressure
Equity
LUPIN
Nomura Maintains Neutral On IGL, Cuts Target Price To Rs 140
Equity
IGL
Parag Milk Foods Reports Higher Revenue But Lower Q2 Consolidated Profit
Equity
PARAGMILK
Nomura Maintains Buy On BEL With Rs 530 Target Price
Equity
BEL
Parag Milk Foods Reports Strong Second Quarter EBITDA Growth And Margin Expansion
Equity
PARAGMILK